Libin Cardiovascular Institute of Alberta, University of Calgary, Calgary, Canada.
Circ Arrhythm Electrophysiol. 2012 Oct;5(5):920-6. doi: 10.1161/CIRCEP.112.974386. Epub 2012 Sep 12.
β-blockers have little effectiveness in preventing vasovagal syncope in unselected populations, but they might be effective in older patients. We determined whether β-blockers prevent vasovagal syncope in an age-related fashion.
Two populations were studied. A proportional hazards analysis was performed on an observational cohort study of 153 patients with vasovagal syncope, 52 of whom received β-blockers. A multivariable proportional hazards model stratified by center was performed on 208 participants in the randomized Prevention of Syncope Trial (POST), examining the interaction between age group and treatment with metoprolol. Age-specific hazard ratios were estimated for both studies and combined using the inverse variance meta-analytic method. In the cohort study, the hazard ratio for syncope if treated with β-blockers was 1.54 (95% CI, 0.78-3.05) for patients aged <42 years and 0.48 (95% CI, 0.12-1.92) for patients aged ≥ 42 years. In POST, the proportional hazards model showed interactions between age and treatment effect (P=0.026). The hazard ratio for patients aged ≥ 42 years who received metoprolol was 0.53 (95% CI, 0.25-1.10); in patients aged <42 years, the hazard ratio was 1.62 (95% CI, 0.85-3.10). A pooled analysis of both studies yielded an estimate of the hazard ratio of 1.58 (CI, 1.00-2.31) for patients aged <42 years, and the hazard ratio was 0.52 (CI, 0.27-1.01) for patients aged ≥ 42 years. The 2 age groups differed significantly in response to β-blockers (P=0.007).
β-blocker treatment may suppress vasovagal syncope in middle-aged patients aged >42 years.
β受体阻滞剂在未选择的人群中预防血管迷走性晕厥的效果很小,但在老年患者中可能有效。我们确定β受体阻滞剂是否以与年龄相关的方式预防血管迷走性晕厥。
研究了两个人群。对血管迷走性晕厥 153 例患者的观察性队列研究进行了比例风险分析,其中 52 例接受了β受体阻滞剂治疗。对预防晕厥试验(POST)的 208 名随机参与者进行了按中心分层的多变量比例风险模型,检查了年龄组和用美托洛尔治疗之间的相互作用。使用逆方差荟萃分析方法估计了两项研究的年龄特异性风险比,并进行了合并。在队列研究中,如果用β受体阻滞剂治疗,<42 岁患者的晕厥风险比为 1.54(95%CI,0.78-3.05),≥42 岁患者的风险比为 0.48(95%CI,0.12-1.92)。在 POST 中,比例风险模型显示年龄和治疗效果之间存在相互作用(P=0.026)。接受美托洛尔治疗的≥42 岁患者的风险比为 0.53(95%CI,0.25-1.10);<42 岁患者的风险比为 1.62(95%CI,0.85-3.10)。对两项研究的汇总分析得出,<42 岁患者的风险比估计值为 1.58(CI,1.00-2.31),≥42 岁患者的风险比为 0.52(CI,0.27-1.01)。两个年龄组对β受体阻滞剂的反应有显著差异(P=0.007)。
β受体阻滞剂治疗可能抑制≥42 岁的中年患者的血管迷走性晕厥。